The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma.

The risk of infection among patients receiving immune checkpoint blockade is unknown. We retrospectively reviewed medical records of 740 patients with melanoma who received immune checkpoint blockers. Serious infection occurred in 54 patients (7.3%). The main risk factors were receipt of corticosteroids and/or infliximab.

[1]  R. Sullivan,et al.  Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. , 2016, JAMA oncology.

[2]  M. Callahan,et al.  Checkpoint Blockade for the Treatment of Advanced Melanoma. , 2016, Cancer treatment and research.

[3]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[4]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[5]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[6]  J. Wolchok,et al.  Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  K. Papadakis,et al.  Ipilimumab-induced colitis in patients with metastatic melanoma , 2015, Melanoma research.

[8]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[9]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[10]  T. Harrer,et al.  Autoimmune Colitis and Subsequent CMV-induced Hepatitis After Treatment With Ipilimumab. , 2015, Journal of immunotherapy.

[11]  R. Krishnan,et al.  Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control , 2015, Oncoimmunology.

[12]  G. Linette,et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. , 2015, The New England journal of medicine.

[13]  M. Postow.  Managing immune checkpoint-blocking antibody side effects. , 2015, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[14]  M. Millenson,et al.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[15]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[16]  J. Wolchok,et al.  Opportunistic infections in patients treated with immunotherapy for cancer , 2014, Journal of Immunotherapy for Cancer.

[17]  A. Hauschild,et al.  Management of immune-related adverse events and kinetics of response with ipilimumab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[19]  S. Almo,et al.  Programmed death-1 (PD-1)–deficient mice are extraordinarily sensitive to tuberculosis , 2010, Proceedings of the National Academy of Sciences.

[20]  J. Montoya,et al.  Prevention and treatment of cancer-related infections. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[21]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  S. Way,et al.  PDL-1 Blockade Impedes T Cell Expansion and Protective Immunity Primed by Attenuated Listeria monocytogenes1 , 2008, The Journal of Immunology.

[23]  Lieping Chen,et al.  Blockade of endogenous B7‐H1 suppresses antibacterial protection after primary Listeria monocytogenes infection , 2008, Immunology.

[24]  K. Sepkowitz,et al.  Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.